Posted: February 15, 2019
Putting Patients First
At Mylan, fighting for patient access to high quality medicines is in our DNA. Over the last few months, we’ve been working harder than ever to ensure that cost savings – made possible by the availability of generic medications – reach patients at the pharmacy counter.
That’s why this week, I’m excited to share another one of Mylan’s success stories that brings more affordability and access to patients. After more than a decade of hard work and more than $700 million in investment, we launched our Wixela™ Inhub™, the first-ever generic to ADVAIR DISKUS® for patients with chronic obstructive pulmonary disease (COPD) in the U.S. This is an important milestone because until now, the brand drug had no generic competition for years, leaving patients – often seniors on fixed incomes – with only one costly option. And we are offering it for a list price 70% less than the brand. This is just one example of what Mylan means by increasing access and putting patients first.
Achieving more wins like this for patients will require sustained commitment and the collective efforts of all of us – the industry, providers and national leadership. I’ve said it before, and I’ll continue to say it until we find a long-term solution: Our healthcare system is broken, and it ultimately hurts patients.
But I believe we are moving in the right direction. I applaud the U.S. Department of Health and Human Services and the Trump administration for their work to bring down drug prices and for understanding the important role generics play in doing so. I’ve long said the best model is one that rewards innovation while encouraging competition, and I am confident more patients will benefit the sooner we all support that framework.
Here at Mylan, we will continue doing our part to address the serious policy and structural issues within the U.S. healthcare system that prevent access. We are committed to doing everything we can to ensure patients actually receive the full benefits of generic alternatives and save on out-of-pocket costs.
Although there are many complicated problems to solve, generics like Wixela Inhub are a critical part of the equation. I remain confident that we can find the right answers if we continue working together to increase access and always prioritize the well-being of patients.